Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
6.08 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 6.222 | 8.559 | 2.132 | 0.537 | 0.072 |
| Gross Profit
| -6.222 | -8.559 | -2.132 | -0.537 | -0.072 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 105.05 | 85.061 | 57.155 | 24.005 | 7.35 |
| General & Administrative Expenses
| 30.481 | 27.323 | 15.727 | 4.005 | 0.644 |
| Selling & Marketing Expenses
| 32.009 | 0 | 0 | 0 | 0 |
| SG&A
| 32.039 | 27.323 | 15.727 | 4.005 | 0.644 |
| Other Expenses
| 0 | 0 | -0.96 | -7.68 | 0.276 |
| Operating Expenses
| 137.089 | 112.384 | 72.882 | 28.01 | 7.994 |
| Operating Income
| -143.311 | -112.384 | -72.882 | -28.01 | -7.994 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 8.297 | 3.883 | -1.076 | -7.869 | 0.254 |
| Income Before Tax
| -135.014 | -108.501 | -73.958 | -35.879 | -7.74 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.338 | -3.883 | -2.016 | 0.189 | 0.277 |
| Net Income
| -135.352 | -104.618 | -71.942 | -36.068 | -8.017 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| EPS
| -2.63 | -2.22 | -1.55 | -0.82 | -0.18 |
| EPS Diluted
| -2.63 | -2.22 | -1.55 | -0.82 | -0.18 |
| EBITDA
| -137.089 | -112.503 | -72.72 | -27.275 | -7.646 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |